These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27872141)

  • 1. Differential roles of RET isoforms in medullary and papillary thyroid carcinomas.
    Lian EY; Maritan SM; Cockburn JG; Kasaian K; Crupi MJ; Hurlbut D; Jones SJ; Wiseman SM; Mulligan LM
    Endocr Relat Cancer; 2017 Jan; 24(1):53-69. PubMed ID: 27872141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
    Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
    Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
    Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
    Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.
    Lindquist D; Alsina FC; Herdenberg C; Larsson C; Höppener J; Wang N; Paratcha G; Tarján M; Tot T; Henriksson R; Hedman H
    Int J Oncol; 2018 Apr; 52(4):1189-1197. PubMed ID: 29436694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
    Zhou D; Li Z; Bai X
    Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
    Kumarasamy VM; Shin YJ; White J; Sun D
    BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
    Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
    Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher
    Mulè C; Ciampi R; Ramone T; Prete A; Matrone A; Cappagli V; Torregrossa L; Basolo F; Elisei R; Romei C
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
    Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
    Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma.
    Lian EY; Hyndman BD; Moodley S; Maritan SM; Mulligan LM
    Oncogene; 2020 Oct; 39(41):6493-6510. PubMed ID: 32884116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation].
    Zhu XL; Zhou XY; Zhang TM; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):87-91. PubMed ID: 16630482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
    Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
    Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
    Romei C; Ciampi R; Elisei R
    Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.